ASH 2020 | Early observations from COVID-19 cases in myeloma patients
Elisabet Manasanch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses early observations of SARS-CoV-2 infections in multiple myeloma patients. She shares the details of a letter to the editor published in Leukemia & Lymphoma in 2020 that discussed findings from COVID-19 cases in myeloma patients early in the pandemic. The symptoms shown and treatments used were typical when compared to other cancer patients. Larger analyses have since shown that the incidence of COVID-19 in myeloma patients is similar to other cancers, as is the infection severity. Dr Manasanch also discusses her thoughts on vaccination in this vulnerable population. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
